ABSTRACT
In order to bridge the gap of information between the in silico model and human subjects, we evaluated torsadogenic risk of cisapride, dl-sotalol, bepridil and verapamil selected from 12 training compounds in the comprehensive in vitro proarrhythmia assay using the chronic atrioventricular block monkeys. Cisapride (0, 1, and 5 mg/kg, n = 5 for each dose), dl-sotalol (0, 1, 3, and 10 mg/kg, n = 5 for each dose), bepridil (0, 10, and 100 mg/kg, n = 4 for each dose), verapamil (0, 1.5, 15, and 75 mg/kg, n = 4 for each dose) were orally administered to the monkeys in conscious state. Five mg/kg of cisapride, 1, 3, and 10 mg/kg of dl-sotalol and 100 mg/kg of bepridil prolonged ΔΔQTcF, which was not observed by verapamil. Torsade de pointes was induced by 5 mg/kg of cisapride in 2 out of 5 animals, by 10 mg/kg of dl-sotalol in 5 out of 5 and by 100 mg/kg of bepridil in 2 out of 4, which was not induced by verapamil. These torsadogenic doses were normalized by their maximum clinical daily ones to estimate torsadogenic risk. The order of risk was dl-sotalol >bepridil ≥cisapride >verapamil in our study. Since the order was bepridil ≥dl-sotalol >cisapride >verapamil in comprehensive in vitro proarrhythmia assay (CiPA) in silico mechanistic model validation, sympathetic regulation on the heart may play a pivotal role in the onset of torsade de pointes in vivo.
Subject(s)
Atrioventricular Block , Torsades de Pointes , Animals , Bepridil , Cisapride/toxicity , Computer Simulation , Macaca fascicularis , Sotalol/toxicity , Torsades de Pointes/chemically induced , Verapamil/toxicityABSTRACT
INTRODUCTION: The abnormal amplification of ventricular repolarization dispersion (VRD) has long been linked to proarrhythmia risk. Recently, the measure of VRD through electrocardiogram intervals has been strongly questioned. The search for an efficient and non-invasive surrogate marker of drug-induced dispersion effects constitute an urgent research challenge. METHODS: Herein, drug-induced ventricular dispersion is generated by d-Sotalol supply in an In-vitro rabbit heart model. A cilindrical chamber simulates the thorax and a multi-electrode net is used to obtain spatial electrocardiographic signals. Cardiac vector dynamics is captured by novel velocity cardiomarkers obtained by quaternion methods. Through statistical analysis and machine learning technics, we compute potential dispersion markers that could define proarrhythmic risk. RESULTS: The cardiomarkers with the greatest statistical significance, both obtained from the electrical cardiac vector, were: the QTω, which is the difference between first and last maxima of angular velocity and λ21vT, the roundness of linear velocity. When comparing with the performance of the current standards (89%), this pair was able to correctly separate 21 out of 22 experiments achieving a performance of 95%. Moreover, the QTω computes in a much more robust basis the QT interval, the current index for drug regulation. DISCUSSION: These velocity markers circumvent the problems of accuratelly finding the fiducial points such as the always tricky T-wave end. Given the high performance they achieved, it is provided a promising outcome for future applications to the detection of anomalous changes of heterogeneity that may be useful for the purposes of torsadogenic toxicity studies.
Subject(s)
Anti-Arrhythmia Agents/toxicity , Arrhythmias, Cardiac/chemically induced , Sotalol/toxicity , Vectorcardiography/methods , Adrenergic beta-Antagonists/toxicity , Animals , Arrhythmias, Cardiac/physiopathology , Biomarkers/metabolism , Heart Ventricles/drug effects , Heart Ventricles/physiopathology , Male , RabbitsABSTRACT
dl-Sotalol which can block both K+ channel and ß-adrenoceptor has been shown to prolong the J-Tpeakc of electrocardiogram in beagle dogs but tended to shorten it in microminipigs, although the drug prolonged the QT interval in both animals under physiologically maintained experimental condition. In order to estimate how the changes in the J-Tpeakc in the normal hearts would be reflected in the pathologic hearts, we compared proarrhythmic effects of dl-sotalol by using proarrhythmia models of beagle dogs and microminipigs, of which atrioventricular node had been ablated > 2 months and 8-9 weeks before, respectively (n = 4 for each species). dl-Sotalol in an oral dose of 10 mg/kg induced torsade de pointes in three out of four beagle dogs, which degenerated into ventricular fibrillation. In microminipigs, the same dose did not trigger torsade de pointes at all, whereas intermittent ventricular pauses were observed in each animal after the drug treatment. These results indicate that assessment of the J-Tpeakc along with the QT-interval prolongation in healthy subjects may provide reliable information of risk prediction for patients susceptible to the drug-induced torsade de pointes.
Subject(s)
Action Potentials/drug effects , Adrenergic beta-Antagonists/toxicity , Heart Conduction System/drug effects , Heart Rate/drug effects , Potassium Channel Blockers/toxicity , Sotalol/toxicity , Torsades de Pointes/chemically induced , Toxicity Tests , Animals , Cardiotoxicity , Dogs , Dose-Response Relationship, Drug , Female , Heart Conduction System/physiopathology , Male , Risk Assessment , Species Specificity , Swine , Swine, Miniature , Torsades de Pointes/physiopathologyABSTRACT
The proarrhythmic potency of drugs is usually attributed to the IKr current block. During safety pharmacology testing analysis of IKr in cardiomyocytes was replaced by human ether-a-go-go-related gene (hERG) test using automated patch-clamp systems in stable transfected cell lines. Aim of this study was to compare the effect of proarrhythmic compounds on hERG and IKr currents and on cardiac action potential. The hERG current was measured by using both automated and manual patch-clamp methods on HEK293 cells. The native ion currents (IKr, INaL, ICaL) were recorded from rabbit ventricular myocytes by manual patch-clamp technique. Action potentials in rabbit ventricular muscle and undiseased human donor hearts were studied by conventional microelectrode technique. Dofetilide, cisapride, sotalol, terfenadine, and verapamil blocked hERG channels at 37°C with an IC50 of 7 nM, 18 nM, 343 µM, 165 nM, and 214 nM, respectively. Using manual patch-clamp, the IC50 values of sotalol and terfenadine were 78 µM and 31 nM, respectively. The IC50 values calculated from IKr measurements at 37°C were 13 nM, 26 nM, 52 µM, 54 nM, and 268 nM, respectively. Cisapride, dofetilide, and sotalol excessively lengthened, terfenadine, and verapamil did not influence the action potential duration. Terfenadine significantly inhibited INaL and moderately ICaL, verapamil blocked only ICaL. Automated hERG assays may over/underestimate proarrhythmic risk. Manual patch-clamp has substantially higher sensitivity to certain drugs. Action potential studies are also required to analyze complex multichannel effects. Therefore, manual patch-clamp and action potential experiments should be a part of preclinical safety tests.
Subject(s)
Action Potentials/drug effects , Anti-Arrhythmia Agents/toxicity , Heart Ventricles/drug effects , Ion Channels/metabolism , Myocytes, Cardiac/drug effects , Potassium Channel Blockers/toxicity , Animals , Drug Evaluation, Preclinical , ERG1 Potassium Channel/metabolism , Female , Heart Ventricles/metabolism , Heart Ventricles/physiopathology , Humans , Male , Myocytes, Cardiac/metabolism , Patch-Clamp Techniques , Phenethylamines/toxicity , Rabbits , Sotalol/toxicity , Sulfonamides/toxicity , Terfenadine/toxicity , Tissue Donors , Verapamil/toxicityABSTRACT
Ivabradine has recently been demonstrated to have antiarrhythmic properties in atrial fibrillation. The aim of the present study was to assess the electrophysiologic profile of ivabradine in an experimental whole-heart model of long-QT-syndrome. In 12 isolated rabbit hearts long-QT-2-syndrome (LQT2) was simulated by infusion of D,L-sotalol (100 µM). 12 rabbit hearts were treated with veratridine (0.5 µM) to mimic long-QT-3-syndrome (LQT3). Sotalol induced a significant prolongation of QT-interval (+ 40 ms, p < 0.01) and action potential duration (APD, + 20 ms, p < 0.01). Similar results were obtained in veratridine-treated hearts (QT-interval: +52 ms, p < 0.01; APD: + 41 ms, p < 0.01). Of note, both sotalol (+ 26 ms, p < 0.01) and veratridine (+ 42 ms, p < 0.01) significantly increased spatial dispersion of repolarisation. Additional infusion of ivabradine (5 µM) did not change these parameters in sotalol-pretreated hearts but resulted in a further significant increase of QT-interval (+ 26 ms, p < 0.05) and APD (+ 49 ms, p < 0.05) in veratridine-treated hearts. Lowering of potassium concentration in bradycardic AV-blocked hearts resulted in the occurrence of early afterdepolarizations (EAD) or polymorphic ventricular tachycardias (VT) resembling torsade de pointes in 6 of 12 sotalol-treated hearts (56 episodes) and 6 of 12 veratridine-treated hearts (73 episodes). Additional infusion of ivabradine increased occurrence of polymorphic VT. Ivabradine treatment resulted in occurrence of EAD and polymorphic VT in 9 of 12 sotalol-treated hearts (212 episodes), and 8 of 12 veratridine-treated hearts (155 episodes). Treatment with ivabradine in experimental models of LQT2 and LQT3 increases proarrhythmia. A distinct interaction with potassium currents most likely represents a major underlying mechanism. These results imply that ivabradine should be employed with caution in the presence of QT-prolongation.
Subject(s)
Anti-Arrhythmia Agents/toxicity , Heart Conduction System/drug effects , Heart Rate/drug effects , Ivabradine/toxicity , Long QT Syndrome/chemically induced , Sotalol/toxicity , Tachycardia, Ventricular/chemically induced , Veratridine/toxicity , Action Potentials/drug effects , Animals , Heart Conduction System/metabolism , Heart Conduction System/physiopathology , Isolated Heart Preparation , Long QT Syndrome/metabolism , Long QT Syndrome/physiopathology , Potassium/metabolism , Rabbits , Risk Assessment , Tachycardia, Ventricular/metabolism , Tachycardia, Ventricular/physiopathology , Time FactorsABSTRACT
INTRODUCTION: Direct comparison of the effects of antiarrhythmic agents on myocardial performance may be useful in choosing between medications in critically ill patients. Studies directly comparing multiple antiarrhythmic medications are lacking. The use of an experimental heart preparation permits examination of myocardial performance under constant loading conditions. METHODS: Hearts of Sprague Dawley rats (n = 35, 402-507 g) were explanted and cannulated in working heart model with fixed preload and afterload. Each heart was then exposed to a 3-hour infusion of procainamide (20 µg/kg/min), esmolol (100 or 200 µg/kg/min), amiodarone (10 or 20 mg/kg/d), sotalol (80 mg/m2/d), or placebo infusions (n = 5 per dose). Cardiac output, contractility (dP/dTmax), diastolic performance (dP/dTmin), and heart rate were compared between groups over time by linear mixed modeling. RESULTS: Compared with placebo, sotalol decreased contractility by an average of 24% ( P < .001) over the infusion period, as did amiodarone (low dose by 13%, P = .029; high dose by 14%, P = .013). Compared with placebo, mean cardiac output was significantly lower in animals treated with sotalol (by 22%, P = .016) and esmolol 200 µg/kg/min (by 23%, P = .012). Over time, amiodarone decreased cardiac output (20 mg/kg/d, ß = -89 [-144, -33] µL/min2 decrease, P = .002) and also worsened diastolic function, decreasing dP/dTmin by â¼18% and 22% ( P = .032 and P = .011, low and high doses, respectively). Procainamide did not have a significant effect on any measures of systolic or diastolic performance. CONCLUSIONS: In isolated hearts, amiodarone and sotalol depressed myocardial contractility, cardiac output, and diastolic function. However, procainamide did not negatively affect myocardial performance and represents a favorable agent in settings of therapeutic equivalence.
Subject(s)
Amiodarone/administration & dosage , Anti-Arrhythmia Agents/administration & dosage , Cardiac Output/drug effects , Myocardial Contraction/drug effects , Procainamide/administration & dosage , Sotalol/administration & dosage , Ventricular Function, Left/drug effects , Amiodarone/toxicity , Animals , Anti-Arrhythmia Agents/toxicity , Dose-Response Relationship, Drug , Infusions, Intravenous , Isolated Heart Preparation , Procainamide/toxicity , Rats, Sprague-Dawley , Risk Assessment , Sotalol/toxicityABSTRACT
Aims: Antazoline is a first-generation antihistamine with antiarrhythmic properties. This study examines potential electrophysiological effects of antazoline in short-QT-syndrome (SQTS) and long-QT-syndrome (LQTS). Methods and results: Sixty-five rabbit hearts were Langendorff-perfused. Action potential duration at 90% of repolarization (APD90), QT-interval, spatial dispersion (DISP), and effective refractory period (ERP) were measured. The IK, ATP-opener pinacidil (1 µM, n = 14) reduced APD90 (-14 ms, P < 0.01), QT-interval (-14 ms, P < 0.01), and ERP (-11 ms, P < 0.01), thus simulating acquired SQTS. Additional infusion of 20 µM antazoline prolonged repolarization. Under baseline conditions, ventricular fibrillation (VF) was inducible in 5 of 14 hearts (10 episodes) and in 5 of 14 pinacidil-treated hearts (21 episodes, P = ns). Antazoline significantly reduced induction of VF (0 episodes, P < 0.05 each). Further 17 hearts were perfused with 100 µM sotalol and 17 hearts with 300 µM erythromycin to induce acquired LQTS2. In both groups, prolongation of APD90, QT-interval, and ERP was observed. Spatial dispersion was increased (sotalol: +26 ms, P < 0.01; erythromycin: +31 ms, P < 0.01). Additional infusion of antazoline reduced DISP (sotalol: -22 ms, P < 0.01; erythromycin: -26 ms, P < 0.01). Torsade de pointes (TdP) occurred in 6 of 17 sotalol-treated (22 episodes, P < 0.05 each) and in 8 of 17 erythromycin-treated hearts (96 episodes P < 0.05 each). Additional infusion of antazoline completely suppressed TdP in both groups (P < 0.05 each). Acquired LQTS3 was induced by veratridine (0.5 µM, n = 17) and similar results were obtained (APD90: +24 ms, P < 0.01, QT-interval: +58 ms, P < 0.01, DISP: +38 ms, P < 0.01). Torsade de pointes occurred in 10 of 17 hearts (41 episodes, P < 0.05 each). Antazoline significantly reduced TdP (2 of 17 hearts, 4 episodes, P < 0.05 each). Conclusion: Antazoline significantly reduced induction of VF in an experimental model of acquired SQTS. In three experimental models of acquired LQTS, antazoline effectively suppressed TdP.
Subject(s)
Action Potentials/drug effects , Antazoline/pharmacology , Arrhythmias, Cardiac/physiopathology , Histamine H1 Antagonists/pharmacology , Long QT Syndrome/physiopathology , Refractory Period, Electrophysiological/drug effects , Torsades de Pointes/physiopathology , Ventricular Fibrillation/physiopathology , Adrenergic beta-Antagonists/toxicity , Animals , Anti-Bacterial Agents/toxicity , Arrhythmias, Cardiac/chemically induced , Disease Models, Animal , Erythromycin/toxicity , Isolated Heart Preparation , Long QT Syndrome/chemically induced , Membrane Transport Modulators/toxicity , Pinacidil/toxicity , Rabbits , Sotalol/toxicity , Torsades de Pointes/chemically induced , Ventricular Fibrillation/chemically inducedABSTRACT
Unmetabolized pharmaceuticals often enter the water treatment plants and exposed to various treatment processes. Among these water treatment processes, disinfection is a process which involves the application of chemical oxidation to remove pathogen. Untreated pharmaceuticals from primary and secondary treatment have the potential to be exposed to the chemical oxidation process during disinfection. This study investigated the kinetics and mechanism of the degradation of sotalol during chlorination process. Chlorination with hypochlorous acid (HOCl) as main reactive oxidant has been known as one of the most commonly used disinfection methods. The second order rate constant for the reaction between sotalol and free available chlorine (FAC) was found to decrease from 60.1 to 39.1M-1min-1 when the pH was increased from 6 to 8. This result was mainly attributed by the decreased of HOCl concentration with increasing pH. In the real water samples, the presence of the higher amount of organic content was found to reduce the efficiency of chlorination in the removal of sotalol. This result showed that sotalol competes with natural organic matter to react with HOCl during chlorination. After 24h of FAC exposure, sotalol was found to produce three stable transformation by-products. These by-products are mainly chlorinated compounds. According to the acute and chronic toxicity calculated using ECOSAR computer program, the transformation by-products are more harmful than sotalol.
Subject(s)
Aquatic Organisms/drug effects , Chlorides/chemistry , Disinfectants/chemistry , Disinfection , Sotalol/analysis , Water Pollutants, Chemical/analysis , Water Purification/methods , Hydrogen-Ion Concentration , Kinetics , Lethal Dose 50 , Models, Theoretical , Oxidation-Reduction , Prognosis , Software , Sotalol/chemistry , Sotalol/toxicity , Water Pollutants, Chemical/chemistry , Water Pollutants, Chemical/toxicityABSTRACT
Monitoring sublethal effects of pharmaceuticals on nontarget species in aquatic environments has become an important topic in ecotoxicology, yet few studies have been conducted concerning the effects of beta-blockers on aquatic organisms. The present study investigated the effects of the beta-blocker sotalol (SOT) at 3 environmentally relevant concentrations on life-history traits of the New Zealand mudsnail Potamopyrgus antipodarum. Based on the pharmacodynamic properties of SOT, the authors hypothesized reduced numbers of embryos in the brood pouches, decelerated growth of adult snails, and smaller size of neonates, but no effect on mortality rates of adults. Contrary to the hypothesis, the total number of embryos was significantly higher after 56 d of exposure at nominal concentrations of 0.05 µg/L and 1.0 µg/L by 107% and 73%, respectively. No differences in embryo numbers were observed at earlier time-points. Therefore, the mode of action seems to be an extension of the reproductive period rather than an increase of the embryo production. Furthermore, our results indicate a hormetic dose-response relationship, because no effects were observed at the highest test-concentration (6.5 µg/L). Mortality, growth of adult snails, and neonate sizes were not affected by the beta-blocker. Given the strong influence on reproduction, the effects of sublethal concentrations of SOT and other beta-blockers deserve better consideration in ecotoxicological risk assessment.
Subject(s)
Adrenergic beta-Antagonists/toxicity , Snails/drug effects , Sotalol/toxicity , Adrenergic beta-Antagonists/analysis , Animals , Dose-Response Relationship, Drug , Female , Fresh Water , Hormesis , New Zealand , Reproduction/drug effects , Risk Assessment , Sotalol/analysis , Water Pollutants, Chemical/analysis , Water Pollutants, Chemical/toxicity , Xenobiotics/analysis , Xenobiotics/toxicityABSTRACT
AIM: The most recent European Society of Cardiology (ESC) update on atrial fibrillation has introduced vernakalant (VER) for pharmacological cardioversion of atrial fibrillation. The aim of the present study was to investigate the safety profile of VER in a sensitive model of proarrhythmia. METHODS AND RESULTS: In 36 Langendorff-perfused rabbit hearts, VER (10, 30 µM, n = 12); ranolazine (RAN, 10, 30 µM, n = 12), or sotalol (SOT, 50; 100 µM, n = 12) were infused after obtaining baseline data. Monophasic action potentials and a 12-lead electrocardiogram showed a significant QT prolongation after application of VER as compared with baseline (10 µM: +25 ms, 30 µM: +50 ms, P < 0.05) accompanied by an increase of action potential duration (APD). The increase in APD90 was accompanied by a more marked increase in effective refractory period (ERP) leading to a significant increase in post-repolarization refractoriness (PRR, 10 µM: +30 ms, 30 µM: +36 ms, P < 0.05). Vernakalant did not affect the dispersion of repolarization. Lowered potassium concentration in bradycardic hearts did not provoke early afterdepolarizations (EADs) or polymorphic ventricular tachycardia (pVT). Comparable results were obtained with RAN. Hundred micromolars of SOT led to an increase in QT interval (+49 ms) and APD90 combined with an increased ERP and PRR (+23 ms). In contrast to VER, 100 µM SOT led to a significant increase in dispersion of repolarization and to the occurrence of EAD in 10 of 12 and pVT in 8 of 12 hearts. CONCLUSION: In the present study, application of VER and SOT led to a comparable prolongation of myocardial repolarization. Both drugs increased the PRR. However, VER neither affect the dispersion of repolarization nor induce EAD and therefore did not cause proarrhythmia.
Subject(s)
Anisoles/toxicity , Anti-Arrhythmia Agents/toxicity , Arrhythmias, Cardiac/chemically induced , Electrophysiologic Techniques, Cardiac , Heart Conduction System/drug effects , Pyrrolidines/toxicity , Acetanilides/toxicity , Action Potentials , Animals , Arrhythmias, Cardiac/diagnosis , Arrhythmias, Cardiac/physiopathology , Heart Conduction System/physiopathology , In Vitro Techniques , Models, Animal , Perfusion , Piperazines/toxicity , Potassium Channel Blockers/toxicity , Rabbits , Ranolazine , Risk Assessment , Risk Factors , Sodium Channel Blockers/toxicity , Sotalol/toxicity , Time FactorsABSTRACT
BACKGROUND AND PURPOSE: During repeat-dose toxicity studies, ECGs are collected from chemically or physically-restrained animals over a short timeframe. This is problematic due to cardiovascular changes caused by manual restraint stress and anesthesia, and limited ECG sampling. These factors confound data interpretation, but may be overcome by using a non-invasive jacket-based ECG collection (JET). The current study investigated whether a jacketed external telemetry system could detect changes in cardiac intervals and heart rate in non-human primates (NHPs), previously implanted with a PCT transmitter. EXPERIMENTAL APPROACH: Twelve male cynomolgus monkeys were treated weekly with vehicle or sotalol (8, 16, 32 mg kg⻹) p.o. ECGs were collected continuously for 24 hours, following treatment, over 4 weeks. A satellite group of six NHPs was used for sotalol toxicokinetics. KEY RESULTS: Sotalol attained Cmax values 1-3 hours after dosing, and exhibited dose-proportional exposure. In jacketed NHPs, sotalol dose-dependently increased QT/QTc intervals, prolonged PR interval, and reduced heart rate. Significant QTc prolongation of 27, 54 and 76 msec was detected by JET after 8, 16, and 32 mg kg⻹ sotalol, respectively, compared with time-matched vehicle-treated animals. Overall, JET-derived PR, QT, QTc intervals, QRS duration, and heart rate correlated well with those derived from PCT. CONCLUSIONS AND IMPLICATIONS: The current findings clearly support the use of JET to quantify cardiac interval and rhythm changes, capable of detecting QTc prolongation caused by sotalol. JET may be a preferred method compared to restraint-based ECG because high-density ECG sampling can be collected in unstressed conscious monkeys, over several weeks.
Subject(s)
Electrocardiography , Heart Rate/physiology , Long QT Syndrome/diagnosis , Telemetry/instrumentation , Telemetry/methods , Animals , Anti-Arrhythmia Agents/pharmacokinetics , Anti-Arrhythmia Agents/pharmacology , Anti-Arrhythmia Agents/toxicity , Data Interpretation, Statistical , Dose-Response Relationship, Drug , Electrodes, Implanted , Long QT Syndrome/drug therapy , Macaca fascicularis , Male , Sotalol/pharmacokinetics , Sotalol/pharmacology , Sotalol/toxicitySubject(s)
Drug-Related Side Effects and Adverse Reactions , Long QT Syndrome/chemically induced , Adult , Anti-Arrhythmia Agents/toxicity , Drug Overdose/complications , Echocardiography , Humans , Male , Poison Control Centers , Practice Guidelines as Topic , Risk Factors , Sotalol/toxicity , Torsades de Pointes/chemically inducedABSTRACT
INTRODUCTION: Dogs are commonly used in cardiovascular drug safety assessment, and implanted telemetry models include subcutaneous or epicardial electrocardiogram (ECG) electrode placements. The purpose of this study was to determine the sensitivity of a canine telemetry model with intravenous ECG lead placement: the negative ECG lead (solid tip) inserted into the jugular vein and the positive lead sutured to the diaphragm. Reference drugs were administered to test the sensitivity to drug-induced changes. METHODS: Twenty-four dogs were implanted with PCT or PCTP transmitters [Data Sciences International (DSI)]. Three reference drugs were administered: sotalol to eight PCT and milrinone to eight PCTP transmitter-implanted dogs. Twenty-four dogs received moxifloxacin (12 dogs/transmitter type). Telemetry data were collected for 25h and analyzed using double Latin squares for sotalol and milrinone data or a 4×4 or 3×6 parallel design for moxifloxacin data. Evaluated parameters were PR, QT, corrected QT (QTc), QRS, heart rate, left ventricular function, and hemodynamic data. Various correction factors for QTc interval were tested. Retrospective power analysis was performed to detect minimal absolute changes comparing a single to a double Latin square or the two parallel designs. RESULTS: Expected changes on ECG and hemodynamic parameters were observed after administration of all reference drugs. The individual animal corrected QT (QTci) interval provided the optimal correction factor. Retrospective power analysis confirmed detection of smaller differences in double versus single Latin squares. Minimal detectable differences were smaller in both Latin squares compared to parallel designs, with smaller detectable differences in a 3×6 compared to a 4×4 parallel design. DISCUSSION: The solid tip intravenous ECG lead configuration in dogs is a viable radiotelemetry model to detect drug-induced changes with high sensitivity. This model yields comparable signal quality and represents a refinement over epicardial ECG leads and allows for possible reduction in the number of animals if study design and size are selected based on needed assay sensitivity.
Subject(s)
Electrocardiography/methods , Electrodes, Implanted , Telemetry/methods , Toxicity Tests/methods , Animals , Aza Compounds/toxicity , Dogs , Fluoroquinolones , Heart Rate/drug effects , Hemodynamics/drug effects , Jugular Veins , Long QT Syndrome/chemically induced , Male , Milrinone/toxicity , Moxifloxacin , Quinolines/toxicity , Sensitivity and Specificity , Sotalol/toxicity , Ventricular Function, Left/drug effectsABSTRACT
This study aimed to comparatively investigate the acute modulating effects of oestrogen and progesterone on the repolarization and the susceptibility of female rabbits to class III anti-arrhythmic agents. The acute influence of estradiol and progesterone on the cardiac repolarization and the drug sensitivity of the rapidly activating delayed rectifier K(+) channel to sotalol was comparatively studied in Langendorff-perfused rabbit hearts at pharmacological concentrations through recording of epicardial monophasic action potentials. In Langendorff-perfused rabbit hearts, estradiol (1-30 µm) concentration-dependently prolonged the monophasic action potential durations (MAPD(30) and MAPD(90) ) (P < 0.05); while the effects of progesterone on MAPD were biphasic: it prolonged MAPD(30) and MAPD(90) at lower concentrations (1-3 µm) but shortened MAPD(30) and MAPD(90) at higher concentrations (10-30 µm). Sotalol-induced prolongation of MAPD(90) was significantly less in the hearts pretreated with progesterone than those treated with estradiol (P < 0.05). The incidence of the pro-arrhythmic events induced by sotalol in the hearts pretreated with progesterone was also significantly lower than those pretreated with estradiol (P < 0.05). In conclusion, estradiol and progesterone have different modulating effects on cardiac repolarization: estradiol can concentration-dependently prolong the cardiac repolarization time and thus may reduce the repolarization reserve and increase the susceptibility of female rabbits to sotalol-induced arrhythmias, whereas progesterone may shorten the cardiac repolarization time at concentrations above 10 µm, thus protecting the heart from drug-induced arrhythmias.
Subject(s)
Arrhythmias, Cardiac/prevention & control , Estradiol/pharmacology , Progesterone/pharmacology , Sotalol/toxicity , Action Potentials/drug effects , Adrenergic beta-Antagonists/pharmacology , Adrenergic beta-Antagonists/toxicity , Animals , Arrhythmias, Cardiac/chemically induced , Dose-Response Relationship, Drug , Estradiol/administration & dosage , Estradiol/metabolism , Female , Pericardium/drug effects , Pericardium/metabolism , Progesterone/administration & dosage , Progesterone/metabolism , Rabbits , Sex Factors , Sotalol/pharmacologyABSTRACT
BACKGROUND: Although the difference in the modulation of estradiol and dihydrotesterone on ventricular repolarization has been intensively studied, little information is available concerning the role of the different ovarian hormones in the modulation of repolarization in the female. METHODS: The chronic modulation of female hormones, estradiol, and progesterone, on cardiac repolarization and the susceptibility to d,l-sotalol, a class III antiarrhythmic agent, were studied in female rabbits by ovariectomy and hormone replacement therapy (HRT) through recording and analyzing of electrocardiograms. RESULTS: The corrected QT interval (QTc) measured 2 weeks after ovariectomy was not significantly different from that in the time-matched control rabbits. After 2 weeks of HRT, the QTc in the ovariectomized rabbits treated with estradiol alone (group E) was not significantly different from that in the control (group C); whereas in the ovariectomized rabbits treated with estradiol plus progesterone (group E + P), it was significantly shorter than those in groups E (P < .05) and C (P < .01), respectively. The corrected Tpeak-end interval (Tpec), an indicator of global dispersion of ventricular repolarization, was also significantly reduced in group E + P compared with that of group C (P < .01). In group E, d,l-sotalol-induced prolongation of QTc and the rate and the severity of arrhythmias were significantly higher, while the dose of sotalol to initiate arrhythmias was significantly lower than those in groups C or E + P, respectively (P < .05 or P < .01). CONCLUSION: Estradiol potentiates QTc prolonging effects of d,l-sotalol and increases the susceptibility to d,l-sotalol-induced arrhythmias without significantly altering QTc itself, whereas progesterone may accelerate the process of repolarization and protect the females from drug-induced arrhythmias, thus counteracting the effect of estradiol.
Subject(s)
Arrhythmias, Cardiac/chemically induced , Estradiol/pharmacology , Progesterone/pharmacology , Sotalol/toxicity , Animals , Anti-Arrhythmia Agents/administration & dosage , Anti-Arrhythmia Agents/toxicity , Arrhythmias, Cardiac/physiopathology , Arrhythmias, Cardiac/prevention & control , Dose-Response Relationship, Drug , Drug Therapy, Combination , Electrocardiography , Estradiol/administration & dosage , Estradiol/toxicity , Estrogen Replacement Therapy/adverse effects , Estrogen Replacement Therapy/methods , Female , Long QT Syndrome/chemically induced , Long QT Syndrome/physiopathology , Long QT Syndrome/prevention & control , Ovariectomy , Progesterone/administration & dosage , Progesterone/toxicity , Rabbits , Severity of Illness Index , Sotalol/administration & dosage , Time FactorsABSTRACT
INTRODUCTION: Similarities between pigs and humans support the relevance of Göttingen minipigs for regulatory safety pharmacology. The minipig is the species of choice for cardiovascular safety pharmacology when pivotal repeat toxicology studies are conducted in this species. METHODS: 4 male Göttingen minipigs with cardiovascular telemetry transmitters received intravenous saline, esmolol (0.5, 1, 2, 4 and 8mg/kg), medetomidine (0.04mg/kg), remifentanil (0.5, 1, 2, 4, 8 and 16µg/kg) and dopamine (2, 8, 10, 20, 30 and 50µg/kg/min) and oral sotalol (3 and 10mg/kg). Respiratory monitoring was conducted in 3 male and 3 female Göttingen minipigs receiving intravenous saline and methacholine (0, 3.4, 13.5 and 68µg/kg). RESULTS: Heart rate (HR) corrected QT was optimal with a method based on analysis of covariance (QTca) followed by Fridericia's standard formula. Esmolol induced a decrease in HR. Medetomidine was associated with an initial hypertension with bradycardia followed by sustained hypotension, bradycadia and prolonged QTc. Remifentanil induced a dose-dependent QTc shortening with an increase in arterial pressures. Sotalol caused a decrease in HR and systolic arterial pressure with an increase in PR and QTc intervals. Dopamine induced an increase in arterial and pulse pressures. Methacholine increased tidal volume, respiratory rate and minute volume. DISCUSSION: The results suggest that the minipig is a valid alternative to other non-rodent species for cardiovascular and respiratory safety pharmacology studies when this species is justified.
Subject(s)
Cardiovascular System/drug effects , Drug Evaluation, Preclinical/methods , Drug-Related Side Effects and Adverse Reactions , Respiratory System/drug effects , Animals , Blood Pressure/drug effects , Dopamine/pharmacology , Dopamine/toxicity , Electrocardiography/drug effects , Electrocardiography/veterinary , Female , Heart Rate , Male , Medetomidine/pharmacology , Medetomidine/toxicity , Models, Animal , Piperidines/pharmacology , Piperidines/toxicity , Propanolamines/pharmacology , Propanolamines/toxicity , Remifentanil , Sotalol/pharmacology , Sotalol/toxicity , Swine , Swine, Miniature , Telemetry/methods , Toxicity Tests/methodsABSTRACT
A new in vivo proarrhythmia model of drug-induced long QT syndrome was developed using the Microminipig, an incredibly small minipig established by Fuji Micra Inc. (Shizuoka). The atrioventricular (AV) node of the Microminipig of either sex weighing approximately 6 - 7 kg was ablated under halothane anesthesia, and proper care was taken for them. Proarrhythmic effects of drugs were assessed at >2 months after the onset of AV block using a Holter recording system. Oral administration of dl-sotalol (10 mg/kg) to the AV-block Microminipig prolonged the QT interval; moreover, it frequently induced dangerous ventricular premature beats, whereas no arrhythmia was detected after the vehicle administration (n = 4). Such dl-sotalol-induced ventricular arrhythmias were not detected in the intact Microminipig with sinus rhythm, although significant QT prolongation was observed (n = 4). Thus, the sensitivity and specificity of the AV-block Microminipig for detecting the drug-induced long QT syndrome can be considered to be comparable to previously established AV-block animal models of dogs and monkeys.
Subject(s)
Atrioventricular Block/chemically induced , Disease Models, Animal , Long QT Syndrome/chemically induced , Sotalol/toxicity , Swine, Miniature , Animals , Arrhythmias, Cardiac/chemically induced , Breeding , Drug Evaluation, Preclinical , Female , Male , SwineABSTRACT
Recent withdrawals of prescription drugs from clinical use because of unexpected side effects on the heart have highlighted the need for more reliable cardiac safety pharmacology assays. Block of the human Ether-a-go go Related Gene (hERG) ion channel in particular is associated with life-threatening arrhythmias, such as Torsade de Pointes (TdP). Here we investigated human cardiomyocytes derived from pluripotent (embryonic) stem cells (hESC) as a renewable, scalable, and reproducible system on which to base cardiac safety pharmacology assays. Analyses of extracellular field potentials in hESC-derived cardiomyocytes (hESC-CM) and generation of derivative field potential duration (FPD) values showed dose-dependent responses for 12 cardiac and noncardiac drugs. Serum levels in patients of drugs with known effects on QT interval overlapped with prolonged FPD values derived from hESC-CM, as predicted. We thus propose hESC-CM FPD prolongation as a safety criterion for preclinical evaluation of new drugs in development. This is the first study in which dose responses of such a wide range of compounds on hESC-CM have been generated and shown to be predictive of clinical effects. We propose that assays based on hESC-CM could complement or potentially replace some of the preclinical cardiac toxicity screening tests currently used for lead optimization and further development of new drugs.
Subject(s)
Drug-Related Side Effects and Adverse Reactions , Embryonic Stem Cells/cytology , Myocytes, Cardiac/cytology , Myocytes, Cardiac/drug effects , Animals , Cell Line , Drug Evaluation, Preclinical , Electrophysiology , Humans , Lidocaine/toxicity , Long QT Syndrome/chemically induced , Mice , Patch-Clamp Techniques , Quinidine/toxicity , Sotalol/toxicityABSTRACT
BACKGROUND AND PURPOSE: The non-selective beta-adrenoceptor antagonist, D,L-sotalol (sotalol) is commonly employed as a positive control during preclinical cardiovascular safety pharmacology testing, mainly because of its ability to prolong QT interval duration. However, no information appears in the literature, except in abstract form, regarding the dose-response effects of sotalol in unanesthetized monkeys. The current study was conducted to determine the dose- and plasma-response effects of orally administered sotalol on cardiovascular function in conscious non-human primates. EXPERIMENTAL APPROACH: Male cynomolgus monkeys were implanted with telemetry devices and the effects of sotalol hydrochloride (5, 10 and 30 mg kg(-1) of body weight, p.o.) on arterial blood pressure, heart rate, body temperature and electrocardiogram waveform were continuously monitored for 6 h after dosing. Blood was sampled for the measurement of plasma concentrations of sotalol. KEY RESULTS: Sotalol dose dependently decreased heart rate and prolonged RR, PR, QT and corrected QT intervals, while having little or no effects on the QRS complex, arterial pressure or body temperature, over the dose range tested. When the data were related to plasma concentrations of sotalol, it was clear that the cardiovascular effects occurred in a similar pattern and to a comparable degree as those reported in human studies. CONCLUSIONS AND IMPLICATIONS: The current study helps demonstrate the validity of utilizing telemetry-instrumented non-human primates for the cardiovascular safety pharmacology assessment of drugs prior to first-in-human testing, and its findings may serve as a reference source for the dose- and plasma-response effects of orally administered sotalol in conscious monkeys.
Subject(s)
Adrenergic beta-Antagonists/toxicity , Electrocardiography , Sotalol/toxicity , Administration, Oral , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/pharmacokinetics , Animals , Blood Pressure/drug effects , Body Temperature/drug effects , Dose-Response Relationship, Drug , Heart Rate/drug effects , Macaca fascicularis , Male , Models, Animal , Sotalol/administration & dosage , Sotalol/pharmacokinetics , Species Specificity , Telemetry/methodsABSTRACT
BACKGROUND: Patients with atrial fibrillation (AF) or congestive heart failure (CHF) are more vulnerable to inappropriate shocks from implantable cardioverter-defibrillators (ICDs), but the effect of antiarrhythmic drugs in these patients remains unknown. METHODS AND RESULTS: A total of 55 patients with AF and/or CHF (New York Heart Association functional class > or =III) who had ICDs were divided into 3 groups [amiodarone (n=24), sotalol (n=12), beta-blocker (n=19)] and the cumulative rates of inappropriate shocks were compared. The baseline characteristics of the 3 groups were not significantly different. The 4-year event rate of inappropriate shocks was 27.3% in the amiodarone group, 54.3% in the sotalol group, and 70.6% in the beta-blocker group (amiodarone vs beta-blocker: log-rank p=0.003; sotalol vs beta-blocker: log-rank p=0.16; amiodarone vs sotalol: log-rank p=0.29). Amiodarone reduced the risk of inappropriate shocks significantly as compared with beta-blockers (hazard ratio (HR) 0.17; 95% confidence interval (CI) 0.05-0.64; p=0.008), whereas sotalol did not (HR 0.57; 95%CI 0.19-1.68; p=0.3). Amiodarone was discontinued in 4 patients (16.7%) because of pulmonary toxicity and the dose was reduced in 4 patients (16.7%) because of a thyroid function abnormality. CONCLUSIONS: Amiodarone is more effective than sotalol or beta-blockers in preventing inappropriate ICD shocks in patients with AF or CHF, but it has a significant risk of drug-related adverse effects.